AMWL vs HIMS Stock Comparison: AI Score, Valuation, Performance and Upside
AMWL is a B2B telehealth infrastructure company serving health systems and payers navigating post-COVID demand normalization, while HIMS is a consumer-facing digital health brand offering telehealth consultations and wellness subscriptions targeting destigmatized health categories. Both are in telehealth but serve fundamentally different customer types.
AMWL vs HIMS compares enterprise B2B telehealth infrastructure against a consumer-facing digital health brand, both competing in the broader telehealth market but with completely different business models and customers.
HIMS holds the edge across 4 of 5 key metrics in this comparison. AMWL has delivered stronger 1-year price return (+139.85% vs -44.48%), though HIMS has the better forward P/E setup (29.03x vs -8.06x for AMWL). HIMS leads on both revenue growth (38.20%) and operating margin (-12.75%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for HIMS (+7.36%) than for AMWL (+0.47%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want enterprise telehealth infrastructure exposure through health system and payer relationships
- See value in Amwell's Converge platform modernization driving customer retention and new wins
- Are comfortable with a slower-growth, more defensive enterprise B2B telehealth investment
- Want consumer digital health brand exposure across men's and women's wellness categories
- See GLP-1 weight management as a significant near-term growth catalyst for Hims & Hers
- Value the recurring subscription model and high customer lifetime value from prescription wellness products
| Metric | AMWL | HIMS |
|---|---|---|
| AI scorei | 23.5 | 42.9 |
| AI ranki | #3509 | #874 |
| Latest closei | $12.52 | $25.24 |
| 1M returni | +1.05% | -12.97% |
| 3M returni | +16.36% | -18.11% |
| 6M returni | +95.02% | -7.44% |
| 1Y returni | +139.85% | -44.48% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AMWL | HIMS |
|---|---|---|
| 1Y ago | $24.6K (+146.0%) started 2025-11-03 | $5.69K (-43.1%) started 2025-11-03 |
| 5Y ago | $654.81 (-93.5%) started 2021-11-03 | $30.56K (+205.6%) started 2021-11-03 |
| 10Y ago | $271.35 (-97.3%) started 2020-09-17 | $25.76K (+157.6%) started 2019-09-13 |
Hypothetical — past performance does not guarantee future results.
| Metric | AMWL | HIMS |
|---|---|---|
| Market capi | $216.69M | $6.79B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -8.06 | 29.03 |
| Price/Salesi | 0.99 | N/A |
| EV/Revenuei | 0.17 | 2.85 |
| Analyst targeti | $12.80 | $31.23 |
| Target upsidei | +0.47% | +7.36% |
| Metric | AMWL | HIMS |
|---|---|---|
| Revenue growthi | -26.60% | 38.20% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | +1.77% | +32.95% |
| Operating margini | -19.59% | -12.75% |
| Profit margini | -35.75% | -5.51% |
| ROIC proxyi | -29.12% | -32.03% |
| Return on equityi | -29.12% | -32.03% |
| Dividend yieldi | 0.00% | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 1.69 | 2.42 |
| Debt/equityi | 1.27 | 477.13 |
| Current ratioi | 2.90 | 0.93 |
| Quick ratioi | 2.72 | 0.82 |
Over the past year, AMWL and HIMS have moved weakly in the same direction (correlation of 0.17), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | AMWL | HIMS |
|---|---|---|---|
| 1Y | Growthi | +145.97% | -43.14% |
| CAGRi | +146.73% | -43.25% | |
| Volatilityi | 73.48% | 89.47% | |
| Sharpe ratioi | 1.53 | -0.26 | |
| Sortino ratioi | 2.78 | -0.40 | |
| Max drawdowni | 25.74% | 67.29% | |
| Current drawdowni | 16.42% | 43.14% | |
| Avg drawdowni | 8.77% | 34.79% | |
| Ulcer Indexi | 10.91% | 37.48% | |
| Max daily dropi | 15.02% | 16.03% | |
| Max wkly dropi | 22.77% | 32.71% | |
| 5Y | Growthi | -93.45% | +205.57% |
| CAGRi | -42.05% | +25.05% | |
| Volatilityi | 78.89% | 84.39% | |
| Sharpe ratioi | -0.37 | 0.63 | |
| Sortino ratioi | -0.57 | 0.98 | |
| Max drawdowni | 98.02% | 78.88% | |
| Current drawdowni | 93.45% | 63.28% | |
| Avg drawdowni | 82.13% | 33.34% | |
| Ulcer Indexi | 84.19% | 38.36% | |
| Max daily dropi | 23.08% | 34.63% | |
| Max wkly dropi | 38.27% | 39.06% | |
| 10Y | Growthi | -97.29% | +157.55% |
| CAGRi | -44.51% | +14.17% | |
| Volatilityi | 78.34% | 77.42% | |
| Sharpe ratioi | -0.43 | 0.50 | |
| Sortino ratioi | -0.65 | 0.77 | |
| Max drawdowni | 99.56% | 87.29% | |
| Current drawdowni | 98.54% | 63.28% | |
| Avg drawdowni | 87.63% | 43.91% | |
| Ulcer Indexi | 90.11% | 52.23% | |
| Max daily dropi | 23.08% | 34.63% | |
| Max wkly dropi | 38.27% | 39.06% |
| Category | AMWL | HIMS |
|---|---|---|
| Company | Amwell (American Well Corporation) | Hims & Hers Health, Inc. |
| Sector | Health Care - Telehealth Platform | Healthcare |
| Industry | Health Information Services | Drug Manufacturers - Specialty & Generic |
| Core business | Amwell provides a telehealth technology platform to health systems, payers, and employers, enabling healthcare organizations to offer virtual care visits across primary care, behavioral health, and specialty care, with its Converge platform as the next-generation infrastructure. | Hims & Hers provides telehealth services and prescription wellness products directly to consumers, addressing men's health (hair loss, sexual health, mental health) and women's health (skincare, birth control, menopause) through a branded digital health and wellness platform. |
| Investor focus | Investors track Amwell's subscription revenue from health system and payer clients, Converge platform adoption, and the company's ability to sustain growth after COVID-era telehealth demand normalization. | Investors track Hims & Hers' subscriber growth, average order value expansion into new health categories, GLP-1 weight loss product opportunities, and revenue per subscriber as category breadth grows. |
- Deep relationships with major health systems and payers as an enterprise telehealth infrastructure provider
- Converge next-generation platform provides a more extensible, modern technical foundation for healthcare partners
- Enterprise B2B model provides more predictable subscription revenue than consumer telehealth models
- Strong consumer brand with destigmatized, direct-to-consumer approach to sensitive health topics
- Subscription model with recurring prescription refills creates predictable revenue
- GLP-1 compounding and weight management category expansion provides a significant near-term growth opportunity
- COVID-era telehealth surge has significantly moderated, pressuring volume and revenue growth
- Competed against large health system-owned solutions and tech giants (Microsoft, Epic) expanding into telehealth infrastructure
- Path to GAAP profitability requires operating leverage that has been difficult to achieve at current revenue levels
- GLP-1 compounding revenue faces regulatory risk as FDA-approved brand availability affects compounding market access
- Consumer health brand building requires ongoing marketing investment to sustain subscriber acquisition
- Must continue expanding into new health categories to sustain growth as original hair loss/sexual health categories mature
Compare more than two at a time
This page is a fixed writeup on AMWL and HIMS. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside AMWL and HIMS, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.